Búsqueda | Portal de Búsqueda de la BVS España

1.

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.

Home, Philip D; McCrimmon, Rory J; Rosenstock, Julio; Blüher, Matthias; Pegelow, Katrin; Melas-Melt, Lydie; Djaballah, Khier; Giorgino, Francesco.

Diabetes Obes Metab; 25(3): 656-663, 2023 03.

Artículo en Inglés | MEDLINE | ID: mdl-36309941

2.

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.

McCrimmon, Rory J; Home, Philip; Cheng, Alice; Giorgino, Francesco; Fonseca, Vivian; Souhami, Elisabeth; Alvarez, Agustina; Picard, Pascaline; Rosenstock, Julio.

Diabetes Obes Metab; 24(12): 2391-2399, 2022 12.

Artículo en Inglés | MEDLINE | ID: mdl-36054624

3.

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

Home, Philip D; Mehta, Roopa; Hafidh, Khadija A S; Gurova, Olesya Y; Alvarez, Agustina; Serafini, Paul; Pourrahmat, Mir-Masoud.

Diabetes Obes Metab; 23(12): 2660-2669, 2021 12.

Artículo en Inglés | MEDLINE | ID: mdl-34402153

4.

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.

Bolli, Geremia B; Landgraf, Wolfgang; Bosnyak, Zsolt; Melas-Melt, Lydie; Home, Philip D.

Diabetes Obes Metab; 22(9): 1664-1669, 2020 09.

Artículo en Inglés | MEDLINE | ID: mdl-32314521

5.

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.

Home, Philip D; Aroda, Vanita R; Blonde, Lawrence; Guyot, Patricia; Shaunik, Alka; Fazeli, Mir Sohail; Goswami, Hardik; Kalra, Sanjay; Pourrahmat, Mir-Masoud.

Diabetes Obes Metab; 22(11): 2170-2178, 2020 11.

Artículo en Inglés | MEDLINE | ID: mdl-32627297

6.

Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.

Home, Philip; Blonde, Lawrence; Kalra, Sanjay; Ji, Linong; Guyot, Patricia; Brulle-Wohlhueter, Claire; Murray, Erin; Shah, Roshan; Sayre, Toby; Shaunik, Alka.

Diabetes Obes Metab; 22(11): 2179-2188, 2020 11.

Artículo en Inglés | MEDLINE | ID: mdl-32700442

7.

Is Insulin Therapy Safe?

Home, Philip; Itzhak, Baruch.

Am J Ther; 27(1): e106-e114, 2020.

Artículo en Inglés | MEDLINE | ID: mdl-31567197

8.

Cardiovascular outcome trials of glucose-lowering medications: an update.

Home, Philip.

Diabetologia; 62(3): 357-369, 2019 03.

Artículo en Inglés | MEDLINE | ID: mdl-30607467

9.

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.

Owens, David R; Landgraf, Wolfgang; Frier, Brian M; Zhang, Mei; Home, Philip D; Meneghini, Luigi; Bolli, Geremia B.

Diabetes Obes Metab; 21(2): 321-329, 2019 02.

Artículo en Inglés | MEDLINE | ID: mdl-30520217

10.

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.

Home, Philip; Calvi-Gries, Francoise; Blonde, Lawrence; Pilorget, Valerie; Berlingieri, Joseph; Freemantle, Nick.

Diabetes Obes Metab; 20(4): 921-929, 2018 04.

Artículo en Inglés | MEDLINE | ID: mdl-29205734

11.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

Home, Philip D; Bergenstal, Richard M; Bolli, Geremia B; Ziemen, Monika; Rojeski, Maria; Espinasse, Melanie; Riddle, Matthew C.

Diabetes Obes Metab; 20(1): 121-128, 2018 01.

Artículo en Inglés | MEDLINE | ID: mdl-28661585

12.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.

Home, Philip D; Lam, Raymond L H; Carofano, Wendy L; Golm, Gregory T; Eldor, Roy; Crutchlow, Michael F; Marcos, Michael C; Rosenstock, Julio; Hollander, Priscilla A; Gallwitz, Baptist.

Diabetes Obes Metab; 20(9): 2220-2228, 2018 09.

Artículo en Inglés | MEDLINE | ID: mdl-29766635

13.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.

Hollander, Priscilla A; Carofano, Wendy L; Lam, Raymond L H; Golm, Gregory T; Eldor, Roy; Crutchlow, Michael F; Marcos, Michael C; Rendell, Marc S; Home, Philip D; Gallwitz, Baptist; Rosenstock, Julio.

Diabetes Obes Metab; 20(9): 2229-2237, 2018 09.

Artículo en Inglés | MEDLINE | ID: mdl-29761615

14.

Tackling obesity during the COVID-19 pandemic.

Akirov, Amit; Cahn, Avivit; Del Prato, Stefano; Home, Philip; Van Gaal, Luc; Chan, Juliana; Ning, Guang; Raz, Itamar.

Diabetes Metab Res Rev; 37(3): e3393, 2021 03.

Artículo en Inglés | MEDLINE | ID: mdl-32797666

15.

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.

Lopes, Renato D; Dickerson, Sheila; Hafley, Gail; Burns, Shana; Tourt-Uhlig, Sandra; White, Jennifer; Newby, L Kristin; Komajda, Michel; McMurray, John; Bigelow, Robert; Home, Philip D; Mahaffey, Kenneth W.

Am Heart J; 166(2): 208-216.e28, 2013 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-23895802

16.

Results of a reevaluation of cardiovascular outcomes in the RECORD trial.

Mahaffey, Kenneth W; Hafley, Gail; Dickerson, Sheila; Burns, Shana; Tourt-Uhlig, Sandra; White, Jennifer; Newby, L Kristin; Komajda, Michel; McMurray, John; Bigelow, Robert; Home, Philip D; Lopes, Renato D.

Am Heart J; 166(2): 240-249.e1, 2013 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-23895806

17.

Insulin biobetters and biosimilars in clinical practice.

Home, Philip.

J R Coll Physicians Edinb; 53(2): 147-155, 2023 06.

Artículo en Inglés | MEDLINE | ID: mdl-37198930

18.

Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.

Heinemann, Lutz; Davies, Melanie; Home, Philip; Forst, Thomas; Vilsbøll, Tina; Schnell, Oliver.

J Diabetes Sci Technol; 17(6): 1649-1661, 2023 11.

Artículo en Inglés | MEDLINE | ID: mdl-35818669

19.

Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.

Home, Philip.

Diabetes Obes Metab; 19(2): 304-305, 2017 02.

Artículo en Inglés | MEDLINE | ID: mdl-27935230

20.

Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.

Hall, Gillian C; McMahon, Alex D; Carroll, Dawn; Home, Philip D.

Pharmacoepidemiol Drug Saf; 21(3): 305-13, 2012 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-22271442

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.

Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.

Is Insulin Therapy Safe?

Cardiovascular outcome trials of glucose-lowering medications: an update.

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.

Tackling obesity during the COVID-19 pandemic.

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.

Results of a reevaluation of cardiovascular outcomes in the RECORD trial.

Insulin biobetters and biosimilars in clinical practice.

Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.

Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.

Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.